Sera Prognostics, Inc.

sera.com

What Do They Do?

Sells the PreTRM blood test and develops other biomarker tests and predictive analytic products and services for pregnant women, physicians, and health care payers.

How Do They Make Money?

Sera earns revenue from sales of PreTRM tests and counts the sale when it delivers test results.

FY2025 revenue

Who Are Their Customers?

Medical professionals order PreTRM tests for pregnant patients, while Sera works with health care providers and payers to support adoption and reimbursement.

Do Revenues Turn Into Profits?

No. It lost $31.9M in FY2025.

Operating income, FY2025

−45067% of revenue

▼ 0% (Loss) vs FY2024 (−$36.6M, −47578%)

Net income, FY2025

−39417% of revenue

▼ −3% (Loss) vs FY2024 (−$32.9M, −42725%)

Free cash flow, FY2025

−32530% of revenue

▲ +85% (Loss) vs FY2024 (−$14.2M, −18500%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +76%; vs $17K in Q2 FY2025
Net income: ▲ +14% (Loss); vs −$8M in Q2 FY2025

Aug 19, 2026 Sera appoints Scott Gleason as CFO Austin Aerts, who had served as CFO, will transition to an advisory role.

Flat. Revenue was $81K in FY2025, about the same as the $82K of FY2021.

Expanded product scope The latest report includes predictive analytic products and services alongside biomarker tests, while the older report describes biomarker tests as its products.

Comments